What is COLUMVI?
COLUMVI (glofitamab-gxbm) is a prescription medicine to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma (LBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory), and who have received 2 or more prior treatments for their cancer.
It is not known if COLUMVI is safe and effective in children.
The conditional approval of COLUMVI is based on response rate and durability of response. There are ongoing studies to establish how well the drug works.
What is the most important information I should know about COLUMVI?
COLUMVI can cause Cytokine Release Syndrome (CRS), a serious side effect that is common during treatment with COLUMVI, and can also be serious and lead to death.
Call your healthcare provider or get emergency medical help right away if you develop any signs or symptoms of CRS, including:
Due to the risk of CRS, you will receive COLUMVI on a “step-up dosing schedule”.
Your healthcare provider will monitor you for CRS during treatment with COLUMVI and may treat you in a hospital if you develop signs and symptoms of CRS. Your healthcare provider may temporarily stop or completely stop your treatment with COLUMVI if you have severe side effects.
Carry the COLUMVI Patient Wallet Card with you at all times and show it to all of your healthcare providers. The COLUMVI Patient Wallet Card lists the signs and symptoms of CRS you should get emergency medical help for right away.
What are the possible side effects of COLUMVI?
COLUMVI may cause serious side effects, including:
The most common side effects of COLUMVI include: CRS, muscle and bone pain, rash, and tiredness.
The most common severe abnormal lab test results with COLUMVI include: decreased white blood cells, decreased phosphate (an electrolyte), increased uric acid levels, and decreased fibrinogen (a protein that helps with blood clotting).
Your healthcare provider may temporarily stop or completely stop treatment with COLUMVI if you develop certain side effects.
Before receiving COLUMVI, tell your healthcare provider about all of your medical conditions, including if you:
Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What should I avoid while receiving COLUMVI?
Do not drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, shaking (tremors), sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of neurologic problems.
These are not all the possible side effects of COLUMVI. Talk to your health care provider for more information about the benefits and risks of COLUMVI.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
Please see Important Safety Information, including Serious Side Effects, as well as the COLUMVI full Prescribing Information and Medication Guide.
Antibody
A special protein made by the immune system (B cells) to help protect from harmful invaders like viruses or bacteria.
B cell
A type of white blood cell in your immune system that helps protect your body from infection and disease.
Bispecific antibody
Bispecific antibodies are designed to target 2 different cells to bring them closer together, such as an immune cell and cancer cell.
Complete remission
Also called “complete response,” it is the disappearance of all signs of cancer in response to treatment. This does not mean the cancer has been cured.
Continuous treatment
Designed for use until disease worsens or unacceptable side effects occur.
Cycle
The time between one round of treatment until the start of the next.
Cytokine release syndrome (CRS)
A serious side effect that happens when your immune system responds too strongly by rapidly releasing a large amount of substances known as cytokines. CRS may cause fever, fast or irregular heartbeat, low blood pressure, chills, or difficulty breathing.
Diffuse large B-cell lymphoma (DLBCL)
A type of aggressive blood cancer that affects B cells. It is the most common form of non-Hodgkin lymphoma.
Fixed-duration therapy
A treatment that is designed to be administered for a prespecified number of cycles and with a targeted completion.
Large B-cell lymphoma (LBCL)
The most common type of B-cell non-Hodgkin lymphoma (NHL). With NHL, abnormal lymphocytes build up in the lymph nodes, bone marrow, and spleen, DLBCL is a subtype of LBCL.
Overall response
A partial or complete remission.
Partial remission
Also called partial response—some measurable decrease in size of the cancer.
Phase 1/2 clinical trial
The first 2 phases of a clinical trial program that studies an investigational treatment.
Refractory
A term used to describe disease that has not responded to treatment.
Relapsed
A term used to describe disease that has returned after responding to previous treatment.
Remission
The reduction in (partial) or disappearance of (complete) signs and symptoms of cancer in response to treatment.
Step-up dose
A smaller dose of COLUMVI that you receive on Day 8 and Day 15 of your first cycle of treatment.
T cell
A type of white blood cell. T cells are part of the immune system and protect the body from infection. They can also help recognize and destroy abnormal cells like cancer cells.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.